tetano
Editor, Senior Moderator
J Med Virol
. 2020 Dec 17.
doi: 10.1002/jmv.26740. Online ahead of print.
Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses
Soumya Sarkar[SUP] 1 [/SUP], Puneet Khanna[SUP] 1 [/SUP], Akhil Kant Singh[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The burden and impact of secondary superadded infections in critically ill coronavirus disease (COVID-19) patients is widely acknowledged. However, there is a dearth of information regarding the impact of COVID-19 in patients with tuberculosis, HIV, chronic hepatitis, and other concurrent infections. This review was conducted to evaluate the consequence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with concurrent co-infections based on the publications reported to date.
Methods: An extensive comprehensive screening was conducted using electronic databases up to 3[SUP]rd[/SUP] September 2020 after obtaining registration with PROSPERO (CRD420202064800). The observational studies or interventional studies in English, evaluating the impact of SARS-CoV-2 in patients with concurrent infections are included for the meta-analyses.
Results: Our search retrieved 20 studies, with a total of 205,702 patients. Patients with Tuberculosis (RR =2.10, 95% CI: 1.75 to 2.51, I[SUP]2[/SUP] =0%), Influenza (RR =2.04, 95% CI: 0.15 to 28.25, I[SUP]2[/SUP] =99%) have an increased risk of mortality during a co-infection with SARS-CoV-2. No significant impact is found in people living with HIV (RR =0.99, 95% CI: 0.82 to 1.19, I[SUP]2[/SUP] =30%), Chronic hepatitis (RR =1.15, 95% CI: 0.73 to 1.81, I[SUP]2[/SUP] =10%). Several countries (Brazil, Paraguay, Argentina, Peru, Colombia, and Singapore) are on the verge of a Dengue co epidemic (cumulative 878496 and 5028380 cases of Dengue and Covid-19 respectively) CONCLUSIONS: The impact of COVID-19 in patients of concurrent infections with either Tuberculosis or Influenza is detrimental. The clinical outcomes of COVID-19 in HIV or Chronic hepatitis patients are comparable to COVID-19 patients without these concurrent infections. This article is protected by copyright. All rights reserved.
Keywords: (COVID-19): coronavirus disease; (SARS-CoV-2): severe acute respiratory syndrome coronavirus-2; Concurrent infections; HIV; Tuberculosis.
. 2020 Dec 17.
doi: 10.1002/jmv.26740. Online ahead of print.
Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses
Soumya Sarkar[SUP] 1 [/SUP], Puneet Khanna[SUP] 1 [/SUP], Akhil Kant Singh[SUP] 1 [/SUP]
Affiliations
- PMID: 33331656
- DOI: 10.1002/jmv.26740
Abstract
Background: The burden and impact of secondary superadded infections in critically ill coronavirus disease (COVID-19) patients is widely acknowledged. However, there is a dearth of information regarding the impact of COVID-19 in patients with tuberculosis, HIV, chronic hepatitis, and other concurrent infections. This review was conducted to evaluate the consequence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with concurrent co-infections based on the publications reported to date.
Methods: An extensive comprehensive screening was conducted using electronic databases up to 3[SUP]rd[/SUP] September 2020 after obtaining registration with PROSPERO (CRD420202064800). The observational studies or interventional studies in English, evaluating the impact of SARS-CoV-2 in patients with concurrent infections are included for the meta-analyses.
Results: Our search retrieved 20 studies, with a total of 205,702 patients. Patients with Tuberculosis (RR =2.10, 95% CI: 1.75 to 2.51, I[SUP]2[/SUP] =0%), Influenza (RR =2.04, 95% CI: 0.15 to 28.25, I[SUP]2[/SUP] =99%) have an increased risk of mortality during a co-infection with SARS-CoV-2. No significant impact is found in people living with HIV (RR =0.99, 95% CI: 0.82 to 1.19, I[SUP]2[/SUP] =30%), Chronic hepatitis (RR =1.15, 95% CI: 0.73 to 1.81, I[SUP]2[/SUP] =10%). Several countries (Brazil, Paraguay, Argentina, Peru, Colombia, and Singapore) are on the verge of a Dengue co epidemic (cumulative 878496 and 5028380 cases of Dengue and Covid-19 respectively) CONCLUSIONS: The impact of COVID-19 in patients of concurrent infections with either Tuberculosis or Influenza is detrimental. The clinical outcomes of COVID-19 in HIV or Chronic hepatitis patients are comparable to COVID-19 patients without these concurrent infections. This article is protected by copyright. All rights reserved.
Keywords: (COVID-19): coronavirus disease; (SARS-CoV-2): severe acute respiratory syndrome coronavirus-2; Concurrent infections; HIV; Tuberculosis.